EUVIMEDEUVIMED entdecken
Open Access

Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response

Israel S Kasago, Walid K Chatila, Cecilia M Lezcano, Christopher A Febres-Aldana, Nikolaus Schultz, Chad Vanderbilt, Snjezana Dogan, Edmund K Bartlett, Sandra P D'Angelo, William D Tap, Samuel Singer, Marc Ladanyi und 3 weitere

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2023.100165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Israel S Kasago und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Melanoma, Sarcoma, Soft Tissue Neoplasms, Histiocytoma, Malignant Fibrous. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The distinction between undifferentiated melanoma (UM) or dedifferentiated melanoma (DM) from undifferentiated or unclassifiable sarcoma can be difficult and requires the careful correlation of clinical, pathologic, and genomic findings. In this study, we examined the utility of mutational signatures to identify patients with UM/DM with particular attention as to whether this distinction matters for treatment because the survival of patients with metastatic melanoma has dramatically improved with immunologic therapy, whereas durable responses are less frequent in sarcomas. We identified 19 cases of UM/DM that were initially reported as unclassified or undifferentiated malignant neoplasm or sarcoma and submitted for targeted next-generation sequencing analysis. These cases were confirmed as UM/DM by harboring melanoma driver mutations, UV signature, and high tumor mutation burden. One case of DM showed melanoma in situ. Meanwhile, 18 cases represented metastatic UM/DM. Eleven patients had a prior history of melanoma. Thirteen of 19 (68%) of the tumors were immunohistochemically completely negative for 4 melanocytic markers (S100, SOX10, HMB45, and MELAN-A). All cases harbored a dominant UV signature. Frequent driver mutations involved BRAF (26%), NRAS (32%), and NF1 (42%). In contrast, the control cohort of undifferentiated pleomorphic sarcomas (UPS) of deep soft tissue exhibited a dominant aging signature in 46.6% (7/15) without evidence of UV signature. The median tumor mutation burden for DM/UM vs UPS was 31.5 vs 7.0 mutations/Mb (P < .001). A favorable response to immune checkpoint inhibitor therapy was observed in 66.6% (12/18) of patients with UM/DM. Eight patients exhibited a complete response and were alive with no evidence of disease at the last follow-up (median 45.5 months). Our findings support the usefulness of the UV signature in discriminating DM/UM vs UPS. Furthermore, we present evidence suggesting that patients with DM/UM and UV signatures can benefit from immune checkpoint inhibitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSarcomaSoft Tissue NeoplasmsHistiocytoma, Malignant FibrousNeoplasms, Second PrimaryHumansImmune Checkpoint InhibitorsBiomarkers, TumorImmunotherapyMutationCutaneous Malignant Melanoma

Stichwörter der Autor:innen

dedifferentiated melanomaimmunotherapy responsemutational signatureundifferentiated melanomaundifferentiated pleomorphic sarcoma

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: hameedm@mskcc.org.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology
  • National Institutes of Health

Zitieren

APA

Kasago, I. S., Chatila, W. K., Lezcano, C. M., Febres-Aldana, C. A., Schultz, N., Vanderbilt, C., Dogan, S., Bartlett, E. K., D'Angelo, S. P., Tap, W. D., Singer, S., Ladanyi, M., Shoushtari, A. N., Busam, K. J., & Hameed, M. (2023). Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100165

Vancouver

Kasago IS, Chatila WK, Lezcano CM, Febres-Aldana CA, Schultz N, Vanderbilt C, et al. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100165

BibTeX
@article{Kasago2023,
  author = {Kasago, Israel S and Chatila, Walid K and Lezcano, Cecilia M and Febres-Aldana, Christopher A and Schultz, Nikolaus and Vanderbilt, Chad and Dogan, Snjezana and Bartlett, Edmund K and D'Angelo, Sandra P and Tap, William D and Singer, Samuel and Ladanyi, Marc and Shoushtari, Alexander N and Busam, Klaus J and Hameed, Meera},
  title = {Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2023.100165}
}
Kostenlos starten →